Clinical trials: Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma
Patients with Multiple Myeloma (MM) are at increased risk of venous thromboembolic event, especially in newly diagnosed patients and during induction treatment with thalidomide in combination with dexamethasone.
- Trial name
- METRO (NCT01508416)
- Where
- 5 sites in France
- Volunteers
- 71 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Newly Diagnosed Multiple Myeloma
Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients
Bortezomib considered the standard of care for treating multiple myeloma patients, the aim was to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly diagnosed patients.
- Trial name
- MM (NCT04348006)
- Testing
- Bortezomib 3.5 MG
- Where
- Iraq
- Sponsor
- Al-Rasheed University College
Newly Diagnosed Multiple Myeloma
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients.
- Trial name
- NCT03948035
- Testing
- Elotuzumab, Carfilzomib, Lenalidomide
- Where
- 56 sites in Austria, Germany
- Volunteers
- 576 people
- Sponsor
- Wuerzburg University Hospital
MULTIPLE MYELOMA (MM)
Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
This study will evaluate the safety and the efficacy of carfilzomib combined with cyclophosphamide and dexamethasone (CCyd) or lenalidomide and dexamethasone (CRd) followed by autologous transplantation ASCT or 12 cycles of…
- Trial name
- FORTE (NCT02203643)
- Testing
- Carfilzomib, Cyclophosphamide, Lenalidomide
- Where
- Italy
- Volunteers
- 477 people
- Sponsor
- Mario Boccadoro
Multiple Myeloma and Plasma Cell Neoplasm
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00526734
- Testing
- filgrastim, pegfilgrastim, melphalan
- Where
- 4 sites in Belgium, Poland
- Volunteers
- 100 people
- Sponsor
- Erasme University Hospital
Multiple Myeloma
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
The purpose of this study is to compare the efficacy of lenalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of lenalidomide and low dose dexamethasone without pembrolizumab in terms of progression-free…
- Trial name
- NCT02579863
- Testing
- Pembrolizumab, Lenalidomide, Dexamethasone
- Volunteers
- 310 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients
This is a single-arm, single-center, open-label clinical study to evaluate the safety and efficacy of GC012F in high-risk, transplant eligible patients with NDMM.
- Trial name
- NCT04935580
- Testing
- GC012F injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Changzheng Hospital
Multiple Myeloma
THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)
The marked activity of thalidomide (thal) and dexamethasone (dex) in relapsed and refractory multiple myeloma (MM) provided the basis for this phase 2 clinical study aimed at investigating the efficacy and toxicity of thal-dex…
- Trial name
- NCT01341262
- Testing
- Thalidomide, Dexamethasone, Zoledronic acid
- Volunteers
- 378 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Newly Diagnosed Multiple Myeloma
A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.
The purpose of this study is to determine whether lenalidomide is safe and effective in the treatment of patients with newly diagnosed Multiple Myeloma who are 65 years of age or older.
- Trial name
- NCT00405756
- Testing
- Lenalidomide: Double-blind Induction, Melphalan, Prednisone
- Where
- 98 sites in Australia, Austria and 20 more
- Volunteers
- 459 people
- Sponsor
- Celgene Corporation
Relapsed/Refractory Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered…
- Trial name
- NCT05259839
- Testing
- Etentamig, Dexamethasone, Lenalidomide
- Where
- 49 sites in United States, Australia and 5 more
- Volunteers
- 283 people
- Sponsor
- AbbVie
Refractory Plasma Cell Myeloma
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
This phase II trial studies the side-effects and anti-cancer effects of giving an autologous or syngeneic stem cell transplant followed by an allogeneic donor stem cell transplant and bortezomib.
- Trial name
- NCT00793572
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Cyclosporine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
The purpose of Phase 1b of the study is to determine the maximum tolerated dose (MTD) of oprozomib in combination with melphalan and prednisone (OMP).
- Trial name
- NCT02072863
- Testing
- Oprozomib, Melphalan, Prednisone
- Where
- 8 sites in Greece, Italy and 1 more
- Volunteers
- 9 people
- Sponsor
- Amgen
Multiple Myeloma
Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy
This is an international,multicenter, prospective, open, double randomised and controlled phase III study to compare the therapeutic efficacy of tandem high dose Melphalan versus triple intermediate dose Melpahaln in…
- Trial name
- NCT00205764
- Testing
- Melphalan
- Where
- Austria
- Volunteers
- 212 people
- Sponsor
- Austrian Forum Against Cancer
Multiple Myeloma
Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])
To understand the safety and efficacy of Revlimid® 2.5mg and 5 mg Capsules (hereinafter referred to as Revlimid) in all patients who are treated with it under the actual condition of use pursuant to the conditions of approval. 1.
- Trial name
- NCT02741544
- Where
- Japan
- Volunteers
- 578 people
- Sponsor
- Celgene
Newly Diagnosed Multiple Myeloma
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
This is a Phase III open-label, 3-arm, parallel, randomized, controlled trial. The allocation ratio 1:1:1 and outcome assessment are blind to group allocation. Patients will be randomized from 3 arms.
- Trial name
- GEM21menos65 (NCT05558319)
- Testing
- Bortezomib, Isatuximab, Iberdomide
- Where
- 68 sites in Spain
- Volunteers
- 480 people
- Sponsor
- PETHEMA Foundation
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease
RATIONALE: Studying the chromosomes in samples of bone marrow and blood in the laboratory from patients with cancer or other blood diseases may help doctors learn more about the disease.
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous/Nonmalignant Condition
- Trial name
- NCT00898066
- Testing
- cytogenetic analysis, fluorescence in situ hybridization
- Volunteers
- 37 people
- Sponsor
- SWOG Cancer Research Network
Newly Diagnosed Multiple Myeloma
Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
This study is to evaluate the combination of isatuximab, iberdomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma participants who are transplant ineligible or not intended for upfront transplant.
- Trial name
- IsaIberVD (NCT07601100)
- Testing
- Isatuximab, Iberdomide, Bortezomib
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma and Plasma Cell Neoplasm
Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide and dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00609167
- Testing
- bortezomib, cyclophosphamide, dexamethasone
- Where
- 2 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)
This study is a Phase Ib open label, single arm, adaptive multicentre trial. Patients with newly diagnosed Multiple Myeloma (MM) will be treated with Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) in combination with…
- Trial name
- CyBorD-Dara (NCT02955810)
- Testing
- Daratumumab, Cyclophosphamide, Bortezomib
- Where
- Ireland
- Volunteers
- 18 people
- Sponsor
- National University of Ireland, Galway, Ireland
Plasma Cell Myeloma
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well ixazomib citrate, lenalidomide, dexamethasone, and daratumumab work in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT03012880
- Testing
- Daratumumab, Dexamethasone, Ixazomib Citrate
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic